Is activation of the reninangiotensin system hazardous to your health?

European Heart Journal

Volumn 32, Issue 17, 2011, Pages 2096-2097

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; RENIN;

ANGIOTENSIN BLOOD LEVEL; ARTERY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; EDITORIAL; HEALTH HAZARD; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; MORTALITY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASOCONSTRICTION; BLOOD; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; FEMALE; HUMAN; MALE; NOTE; PERIPHERAL VASCULAR DISEASE;

CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; RENIN;

EID: 80052472247     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr074     Document Type: Editorial

References (9)

1. Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, Yusuf S, Lonn EM. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011;32:2135-2142. First published on 17 March 2011. doi:10.1093/eurheartj/ehr066.
2. Sealey JE, Gerten-Banes J, Laragh JH. The renin system: variations in man measured by radioimmunoassay and bio-assay. Kidney Int 1972;1:240-253.
3. Laragh JH. Renin profiling for diagnosis, risk assessment and treatment of hypertension. Kidney Int 1993;44:1163-1175.
4. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8. (Pubitemid 27038966)
5. Cohn JN. Vasodilator therapy for heart failure: the influence of impedance on left ventricular performance. Circulation 1973;48:5-8.
6. Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978;58:763-770. (Pubitemid 9042756)
7. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Editorial. Circulation 1995;91:2504-2507.
8. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993;87:VI-40-VI-48. (Pubitemid 23164221)
9. Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, Cohn JN on behalf of the Val-HeFT Investigators. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2010;16:964-970.